12.92
price down icon1.00%   -0.13
after-market Dopo l'orario di chiusura: 12.90 -0.02 -0.15%
loading
Precedente Chiudi:
$13.05
Aprire:
$13.02
Volume 24 ore:
1.40M
Relative Volume:
0.84
Capitalizzazione di mercato:
$40.96B
Reddito:
$30.27B
Utile/perdita netta:
$1.93B
Rapporto P/E:
21.38
EPS:
0.6044
Flusso di cassa netto:
$3.45B
1 W Prestazione:
-0.23%
1M Prestazione:
-3.29%
6M Prestazione:
-5.69%
1 anno Prestazione:
-13.06%
Intervallo 1D:
Value
$12.92
$13.04
Intervallo di 1 settimana:
Value
$12.86
$13.20
Portata 52W:
Value
$12.57
$15.08

Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile

Name
Nome
Takeda Pharmaceutical Co Adr
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
49,281
Name
Cinguettio
@takedapharma
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
TAK's Discussions on Twitter

Confronta TAK con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
12.92 40.96B 30.27B 1.93B 3.45B 0.6044
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
165.89 74.84B 9.15B 2.43B 2.31B 5.32
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.24 41.78B 14.26B 1.55B 0 0.3383
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
21.92 24.83B 16.77B -959.00M 1.37B -0.85
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
143.26 14.50B 2.24B 385.90M 440.10M 3.73

Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-03-16 Aggiornamento BofA Securities Neutral → Buy
2022-07-19 Aggiornamento Cowen Market Perform → Outperform
2021-10-07 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-04-19 Downgrade JP Morgan Overweight → Neutral
2019-11-01 Iniziato Cowen Market Perform
2019-08-15 Downgrade Daiwa Securities Outperform → Neutral
Mostra tutto

Takeda Pharmaceutical Co Adr Borsa (TAK) Ultime notizie

pulisher
Jan 17, 2025

Global Pharma & Biotech CRM Software Market To Surpass Valuation of US$ 20.0 Billion by 2033 | Astute Analytica - GlobeNewswire Inc.

Jan 17, 2025
pulisher
Jan 14, 2025

Weekly Upgrades and Downgrades - InvestorPlace

Jan 14, 2025
pulisher
Nov 30, 2024

Saudi Arabia Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research

Nov 30, 2024
pulisher
Nov 28, 2024

Dr. Kevan Jacobson and Dr. Genelle Lunken Awarded $1M Pioneer Grant for Transformative Pediatric Research in Inflammatory Bowel Disease - Quantisnow

Nov 28, 2024
pulisher
Nov 22, 2024

Things To Consider Before You Buy Takeda Pharmaceutical Co ADR (NYSE: TAK) - Stocks Register

Nov 22, 2024
pulisher
Nov 22, 2024

Capital One Financial Corp (NYSE: COF): Overvalued In Comparison To Others? - Stocks Register

Nov 22, 2024
pulisher
Nov 21, 2024

Takeda and Alloy Therapeutics partner to make off-the-shelf CAR-T therapies - MSN

Nov 21, 2024
pulisher
Nov 20, 2024

Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform - Quantisnow

Nov 20, 2024
pulisher
Nov 20, 2024

Australia Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research

Nov 20, 2024
pulisher
Nov 20, 2024

Denmark Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research

Nov 20, 2024
pulisher
Nov 18, 2024

Italy Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research

Nov 18, 2024
pulisher
Nov 18, 2024

UK Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research

Nov 18, 2024
pulisher
Nov 18, 2024

South Africa Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research

Nov 18, 2024
pulisher
Nov 06, 2024

T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - GlobeNewswire Inc.

Nov 06, 2024
pulisher
Nov 05, 2024

Asian Equities Traded in the US as American Depositary Receipts Tumble in Wednesday Trading - MSN

Nov 05, 2024
pulisher
Nov 03, 2024

Earnings call: Takeda reports robust H1 growth, revises full-year guidance - Investing.com Australia

Nov 03, 2024
pulisher
Nov 03, 2024

Earnings call: Takeda reports robust H1 growth, revises full-year guidance By Investing.com - Investing.com South Africa

Nov 03, 2024
pulisher
Nov 02, 2024

Torm Plc (NASDAQ: TRMD): Getting A Free Pass? - Stocks Register

Nov 02, 2024
pulisher
Nov 02, 2024

What Analysts Were Expecting After Checkpoint Therapeutics Inc (NASDAQ: CKPT) rose 2.03% - Stocks Register

Nov 02, 2024
pulisher
Oct 21, 2024

Spain Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research

Oct 21, 2024
pulisher
Oct 21, 2024

Thailand Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research

Oct 21, 2024
pulisher
Oct 16, 2024

Dyne Therapeutics Inc (DYN) gets rating Reiterated from Chardan Capital Markets - Knox Daily

Oct 16, 2024
pulisher
Oct 16, 2024

W & T Offshore Inc (WTI) receives a Buy rating from Stifel - Knox Daily

Oct 16, 2024
pulisher
Oct 16, 2024

JP Morgan Upgrades Mister Car Wash Inc (MCW) to an Overweight from a Neutral - Knox Daily

Oct 16, 2024
pulisher
Oct 16, 2024

BofA Securities upgrades Takeda Pharmaceutical Co ADR (TAK) rating to a Buy - Knox Daily

Oct 16, 2024
pulisher
Oct 16, 2024

What Did We Find About Insider Trading At Ovintiv Inc (NYSE: OVV)? - Stocks Register

Oct 16, 2024
pulisher
Oct 15, 2024

Mizuho analysts downgrades a Neutral rating for Squarespace Inc (SQSP) - Knox Daily

Oct 15, 2024

Takeda Pharmaceutical Co Adr Azioni (TAK) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
drug_manufacturers_specialty_generic HLN
$9.24
price up icon 0.54%
$21.92
price up icon 1.11%
$143.26
price up icon 0.94%
$11.30
price down icon 0.35%
$126.20
price down icon 0.05%
Capitalizzazione:     |  Volume (24 ore):